Outcome

Mild hyperbaric oxygen therapy at 1.25 ATA with 36% oxygen administered for 3 hours daily over 16 weeks significantly improved metabolic health and muscle oxidative capacity in rats with metabolic syndrome. The therapy resulted in reductions in fasting and nonfasting blood glucose glycated hemoglobin total cholesterol triglycerides insulin levels and systolic blood pressure.

Introduction

Metabolic syndrome is a cluster of conditions that significantly increase the risk of heart disease stroke and diabetes. It is characterized by high blood pressure elevated blood glucose levels abnormal cholesterol levels and excess body fat around the waist. Conventional treatments often include lifestyle changes and medications but emerging therapies aim to provide additional avenues for managing this complex metabolic disorder. This study investigates the potential of mild hyperbaric oxygen therapy (HBOT) at 1.25 atmospheres absolute (ATA) with 36% oxygen in improving metabolic health and muscle oxidative capacity.

Conducted over 16 weeks using a rat model the research examines whether daily exposure to these specific hyperbaric conditions can favorably impact various health markers associated with metabolic syndrome. Key outcomes include reductions in fasting and nonfasting blood glucose levels glycated hemoglobin total cholesterol triglycerides insulin and systolic blood pressure. Additionally the study explores the therapy’s influence on adiponectin levels and muscle oxidative metabolism demonstrated by changes in succinate dehydrogenase (SDH) activity and mRNA levels of peroxisome proliferator-activated receptor γ coactivator-1α (Pgc-1α). The findings suggest that mild HBOT could be an effective strategy in managing metabolic syndrome and mitigating its associated cardiovascular risks.

Results

The study evaluated the effects of mild hyperbaric oxygen therapy (HBOT) at 1.25 atmospheres absolute (ATA) with 36% oxygen for 3 hours daily over 16 weeks on rats with metabolic syndrome. The therapy resulted in significant improvements in metabolic health and muscle oxidative capacity in the treated rats. Specifically there was a notable reduction in fasting and nonfasting blood glucose glycated hemoglobin total cholesterol triglycerides insulin and systolic blood pressure levels. Additionally there was an elevation in adiponectin levels which is beneficial for metabolic health.

In terms of muscle health the treated rats demonstrated increased activity of succinate dehydrogenase (SDH) and higher mRNA levels of peroxisome proliferator-activated receptor γ coactivator-1α (Pgc-1α) in the soleus muscle indicating enhanced oxidative metabolism. The muscle fiber composition also shifted favorably with a decrease in the percentage of type I fibers and an increase in type IIA fibers along with greater SDH staining intensity in type I and type IIC fibers.

Importantly no significant differences were observed between the treated rats and the normobaric Wistar rat control group suggesting that the mild hyperbaric conditions effectively normalized the metabolic and muscle oxidative profiles of the rats with metabolic syndrome to those of healthy control rats.

Overall these findings suggest that mild HBOT can significantly improve blood glucose levels lipid profiles and muscle oxidative capacity in rats with metabolic syndrome thereby potentially reducing associated cardiac risks.

Conclusion

In summary this study underscores the significant therapeutic potential of mild hyperbaric oxygen therapy (HBOT) in alleviating the symptoms of metabolic syndrome and reducing associated cardiovascular risks. Over a 16-week period rats subjected to a mild hyperbaric environment (1.25 ATA with 36% oxygen) for 3 hours daily displayed marked improvements in metabolic health indicators. Specifically these rats demonstrated lowered fasting and nonfasting blood glucose reduced glycated hemoglobin decreased total cholesterol triglycerides insulin and systolic blood pressure levels when compared to control rats under normobaric conditions. Additionally the treated rats showed increased adiponectin levels and enhanced muscle oxidative capacity evidenced by elevated succinate dehydrogenase activity and higher mRNA levels of Pgc-1α in the soleus muscle.

The therapy also fostered beneficial alterations in muscle fiber composition favoring more oxidative fibers which are indicative of enhanced muscle metabolism. Importantly these positive changes in the CP-H group brought their metabolic and muscle oxidative profiles closer to those observed in healthy control rats (WR).

These findings highlight the potential of mild HBOT as a non-invasive innovative approach to managing metabolic syndrome. Future research should focus on understanding the underlying mechanisms and evaluating the long-term efficacy and safety of this therapy in human subjects. The promising results from this study pave the way for clinical trials and further investigations to validate the practical applications of mild HBOT in improving metabolic health and reducing cardiovascular complications.